| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 469 | 2021 |
| Why has model‐informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future AS Darwich, K Ogungbenro, AA Vinks, JR Powell, JL Reny, N Marsousi, ... Clinical Pharmacology & Therapeutics 101 (5), 646-656, 2017 | 204 | 2017 |
| Effect of convalescent plasma on organ support–free days in critically ill patients with COVID-19: a randomized clinical trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 187 | 2021 |
| Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study J Galea, K Ogungbenro, S Hulme, A Greenhalgh, L Aarons, S Scarth, ... Journal of Cerebral Blood Flow & Metabolism 31 (2), 439-447, 2011 | 126 | 2011 |
| The population pharmacokinetics of R‐ and S‐warfarin: effect of genetic and clinical factors S Lane, S Al‐Zubiedi, E Hatch, I Matthews, AL Jorgensen, P Deloukas, ... British journal of clinical pharmacology 73 (1), 66-76, 2012 | 111 | 2012 |
| Reduction of inflammation after administration of interleukin-1 receptor antagonist following aneurysmal subarachnoid hemorrhage: results of the Subcutaneous Interleukin-1Ra in … J Galea, K Ogungbenro, S Hulme, H Patel, S Scarth, M Hoadley, ... Journal of neurosurgery 128 (2), 515-523, 2017 | 106 | 2017 |
| Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy AS Darwich, TM Polasek, JK Aronson, K Ogungbenro, DFB Wright, ... Annual review of pharmacology and toxicology 61, 225-245, 2021 | 97 | 2021 |
| Methods and software tools for design evaluation in population pharmacokinetics–pharmacodynamics studies J Nyberg, C Bazzoli, K Ogungbenro, A Aliev, S Leonov, S Duffull, ... British journal of clinical pharmacology 79 (1), 6-17, 2015 | 93 | 2015 |
| Capsaicin-evoked cough responses in asthmatic patients: evidence for airway neuronal dysfunction I Satia, N Tsamandouras, K Holt, H Badri, M Woodhead, K Ogungbenro, ... Journal of Allergy and Clinical Immunology 139 (3), 771-779. e10, 2017 | 92 | 2017 |
| Optimal design of pharmacokinetic studies L Aarons, K Ogungbenro Basic & clinical pharmacology & toxicology 106 (3), 250-255, 2010 | 87 | 2010 |
| Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... Jama 329 (1), 39-51, 2023 | 80 | 2023 |
| Optimal design for multivariate response pharmacokinetic models I Gueorguieva, L Aarons, K Ogungbenro, KM Jorga, T Rodgers, ... Journal of Pharmacokinetics and Pharmacodynamics 33, 97-124, 2006 | 71 | 2006 |
| Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug–drug interactions F Salem, TN Johnson, ZE Barter, JS Leeder, A Rostami‐Hodjegan The Journal of Clinical Pharmacology 53 (8), 857-865, 2013 | 66 | 2013 |
| Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B‐mediated drug–drug interactions using population pharmacokinetic modeling and simulation S Barnett, K Ogungbenro, K Ménochet, H Shen, Y Lai, WG Humphreys, ... Clinical Pharmacology & Therapeutics 104 (3), 564-574, 2018 | 65 | 2018 |
| Advanced methods for dose and regimen finding during drug development: summary of the EMA/EFPIA workshop on dose finding (London 4–5 December 2014) FT Musuamba, E Manolis, N Holford, SYA Cheung, LE Friberg, ... CPT: pharmacometrics & systems pharmacology 6 (7), 418-429, 2017 | 65 | 2017 |
| A program for individual and population optimal design for univariate and multivariate response pharmacokinetic–pharmacodynamic models I Gueorguieva, K Ogungbenro, G Graham, S Glatt, L Aarons Computer methods and programs in biomedicine 86 (1), 51-61, 2007 | 63 | 2007 |
| Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modeling and simulation and cost analysis K Ogungbenro, A Patel, R Duncombe, R Nuttall, J Clark, P Lorigan Clinical Pharmacology & Therapeutics 103 (4), 582-590, 2018 | 62 | 2018 |
| Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial REMAP-CAP Investigators, LPG Derde, AC Gordon, PR Mouncey, ... MedRxiv, 2021.06. 18.21259133, 2021 | 59 | 2021 |
| Pharmacokinetic modelling of interleukin‐1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage I Gueorguieva, SR Clark, CJ McMahon, S Scarth, NJ Rothwell, PJ Tyrell, ... British journal of clinical pharmacology 65 (3), 317-325, 2008 | 59 | 2008 |
| Anakinra in COVID-19: important considerations for clinical trials A King, A Vail, C O'Leary, C Hannan, D Brough, H Patel, J Galea, ... The Lancet Rheumatology 2 (7), e379-e381, 2020 | 53 | 2020 |
